INTRODUCTION AND OBJECTIVES: Level I evidence supports the utility of neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (BCa). Although this evidence is derived primarily from phase III trials that used the combination of methotrexate/vinblastine/ doxorubicin/cisplatin (MVAC) or cisplatin/methotrexate/vinblastine (CMV), the alternative and less toxic regimen gemcitabine/cisplatin (GC) is currently used more commonly for NAC. Since dose dense (dd)-MVAC has mostly replaced traditional MVACOur primary endpoint was to assess the rate of pT0N0 and pT1N0 for patients with BCa treated with the accelerated or dose dense MVAC (ddMVAC) chemotherapy followed by radical cystectomy (RC) in this real-word multi-institutional cohort.
INTRODUCTION AND OBJECTIVES: Level I evidence supports the utility of neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (BCa) . Although this evidence is derived primarily from phase III trials that used the combination of methotrexate/vinblastine/ doxorubicin/cisplatin (MVAC) or cisplatin/methotrexate/vinblastine (CMV), the alternative and less toxic regimen gemcitabine/cisplatin (GC) is currently used more commonly for NAC. Since dose dense (dd)-MVAC has mostly replaced traditional MVACOur primary endpoint was to assess the rate of pT0N0 and pT1N0 for patients with BCa treated with the accelerated or dose dense MVAC (ddMVAC) chemotherapy followed by radical cystectomy (RC) in this real-word multi-institutional cohort.
METHODS: We retrospectively reviewed records of patients with urothelial cancer who underwent ddMVAC and RC at seven contributing institutions from 2000-2015. Patients with cT2-4a,M0 BCa were included. Presence of cT3-4 disease, hydronephrosis, lymphovascular invasion and/or existence of sarcomatoid, or micropapillary features on the initial transurethral resection of bladder tumor specimen was defined as high-risk disease. Logistic regression models for prediction of pT0N0 and pT1N0 were generated for the entire cohort as well as for the cN0 subgroup. The multivariable Cox proportional hazards regression model for survival using post RC data was used to assess hazard ratios (HRs) for the variables of interest.
RESULTS: A total of 345 patients received ddMVAC chemotherapy during the study period. The observed rates of pT0N0 and pT1N0 were 30.4% and 49.3%, respectively among cN0 patients. On the multivariable regression model, the presence of more than one clinical high-risk element was associated with 70% (OR 0.30 95%CI (0.10-0.86); p¼0.02) reduction in the probability of achieving partial pathological response.
CONCLUSIONS: A complete response (pT0N0) was observed in one third of patients after neoadjuvant ddMVAC therapy, and a partial response (pT1N0) was observed in nearly half of the cases in this real-world experience with this regimen. To our knowledge, this represents the largest experience outside clinical trial settings. (BCa) . Although this evidence is derived primarily from phase III trials that used the combination of methotrexate/vinblastine/ doxorubicin/cisplatin (MVAC) or cisplatin/methotrexate/vinblastine (CMV), the alternative and less toxic regimen gemcitabine/cisplatin (GC) is currently used more commonly for NAC. Since dose dense (dd)-MVAC has mostly replaced traditional MVAC, we aimed to compare pathological response and survival rates in patients with locally advanced BCa receiving ddMVAC versus GC.
Source of Funding: None
METHODS: We retrospectively reviewed records of patients with urothelial cancer who received NAC and underwent cystectomy at 19 contributing institutions from 2000-2013. Patients with cT3-4aN0M0 were selected for this analysis. The rate of pT0N0 and pT1N0 was compared between GC and ddMVAC regimens. A Multivariable Cox proportional hazards regression model for overall mortality was generated to evaluate hazard ratios (HRs) for variables of interest (age, LVI, hydronephrosis, type of chemotherapy regimen, surgical margin).
RESULTS: Of 1865 patients undergoing NAC and RC during the study period, 319 met our inclusion criteria (table 1) . A significantly lower rate of pT0N0 was observed in the GC arm compared to ddMVAC (14.6% vs. 28.0%; p¼0.005). The rate of pT1N0 was 30.1% for GC compared to 41.0% for ddMVAC (p¼0.07). The Kaplan-Meier mean estimate of overall survival for GC and ddMVAC patients was 4.2 and 7.0 years, respectively (p¼0.001). In multivariable cox regression analysis, GC patients were at higher risk of death compared to ddMVAC patients (HR 1.9, 95%CI (1.2-3.1); p¼0.006). Presence of LVI (HR 2.1, 95%CI (1.2-3.6); p¼0.007), hydronephrosis (HR 1.9, 95%CI (1.3-2.9); p¼0.002) and positive surgical margin (HR 1.4, 95%CI (1.2-1.7); p<0.001) were also associated with higher risk of death.
CONCLUSIONS: In our retrospective cohort of locally advanced BCa patients, ddMVAC was associated with a higher rate of pathologic down-staging response and improved longer survival when compared to GC. A clinical trial is warranted to validate these hypothesis-generating results superiority of neoadjuvant ddMVAC in patients with locally advanced BCa. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e773
